A non-profit 501(c)(3) premium and copayment foundation
Drug manufacturers and the insurance industry argue over which is more to blame for high out-of-pocket costs for specialty tier drugs, while a separate study concludes that Marketplace plans turning out to be less costly than non-Marketplace plans. Despite wide variations, proposed Marketplace premiums for 2015 continue to average in the low double-digit range, consistent with the pre-ACA market. A federal court decision blocks proposed rules extending 340B drug discounts to orphan drugs, as required by the ACA.
You can find the full Health Reform Update here. If you’re interested in Advocacy, you can also join the PSI Patient Coalition here.